부산대학교 도서관

Abstract: Hepatitis C virus (HCV) infection is a common problem in patients treated with maintenance hemodialysis (HD) and is associated with an increased morbidity and mortality and lower quality of life. The major causes of HCV‐associated mortality are liver and cardiovascular‐related death. HCV‐infected HD patients have a higher prevalence of inflammation‐related metabolic and vascular diseases, leading to high rates of cardiovascular mortality in patients with end‐stage renal disease. In the current era of highly effective direct‐acting antiviral regimens, HCV treatment may also confer hepatic, cardiovascular and other morbidity and mortality benefits even to dialysis‐dependent patients who do not qualify for kidney transplantation. Currently, the most accepted regimens in this patient population include elbasvir/grazoprevir and glecaprevir/pibrentasvir [ABSTRACT FROM AUTHOR]